Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 401 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Events Clear all
Terminated Phase 3 Interventional Results available

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

NCT01609582
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
TAK-875, TAK-875 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
3,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
218
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jun 7, 2026, 9:24 AM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

NCT01331837
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
3,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting No phase listed Observational

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

NCT06567795
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease
Interventions
Hemotag
Device
Lead sponsor
Aventusoft, LLC.
Industry
Eligibility
40 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
108
States / cities
Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional

Intensive Discharge Intervention in Diabetes

NCT02122926
View directory record Official record
Conditions
Type II Diabetes, Cardiovascular Disease
Interventions
Intensive discharge intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Jun 7, 2026, 9:24 AM EDT
Terminated Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

NCT04895410
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lemzoparlimab, Dexamethasone, Carfilzomib, Pomalidomide, Daratumumab
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position

NCT01546636
View directory record Official record
Conditions
Cerebral Ischemia
Interventions
Hypocapnic group, Normocapnic group
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jun 7, 2026, 9:24 AM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jun 7, 2026, 9:24 AM EDT
Withdrawn No phase listed Observational

MACE CDS Software Master Enrollment Protocol

NCT06257628
View directory record Official record
Conditions
Cardiac Events
Interventions
Index Event
Device
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
23 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

NCT00153101
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
31,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
100
States / cities
Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jun 7, 2026, 9:24 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jun 7, 2026, 9:24 AM EDT
Completed No phase listed Observational

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

NCT00875238
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
Interventions
trastuzumab, doxorubicin hydrochloride, polymorphism analysis, laboratory biomarker analysis, questionnaire administration, assessment of therapy complications, magnetic resonance imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting Phase 3 Interventional

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060
View directory record Official record
Conditions
Heart Failure
Interventions
Baxdrostat and dapagliflozin, Placebo and dapagliflozin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
11,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
194
States / cities
Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 3 Interventional

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

NCT01042769
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Aleglitazar, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
7,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
221
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

NCT01968980
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

NCT00552188
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-438
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Telephone Assessment and Skill-Building Intervention for Stroke Caregivers

NCT01275495
View directory record Official record
Conditions
Stroke, Family Caregivers
Interventions
Telephone Assessment and Skill-Building Kit (TASK II), Information, Support, and Referral (ISR)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

The Gore SCAFFOLD Clinical Study

NCT01901874
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis
Interventions
Carotid Artery Stenting
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Honolulu, Hawaii • Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Jun 7, 2026, 9:24 AM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

Positive Emotions Following Acute Cardiac Events

NCT05412862
View directory record Official record
Conditions
Acute Coronary Syndrome, Physical Inactivity
Interventions
Positive Psychology + Motivational Interviewing
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Withdrawn Not applicable Interventional

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase

NCT03791580
View directory record Official record
Conditions
Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event
Interventions
Commitment nudge, Justification nudge
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 7, 2026, 9:24 AM EDT